Press Release

BioNTech Recognizes Employees and Partners for Their Support in Developing Historic Vaccine

31 December 2020

MAINZ, Germany, December 31, 2020BioNTech SE (Nasdaq: BNTX) today wants to express its thanks and gratitude not only to its employees but also to the many partners who have assisted the company in successfully developing a vaccine for COVID-19. BioNTech acknowledges that without the tireless effort from its’ employees and partners, who have played a pivotal role in this effort, it would not have been able to achieve this historic company milestone, a journey which only began in early 2020. Data from its Phase 3 study have demonstrated that the vaccine is well-tolerated and 95% effective in preventing COVID-19. The vaccine has already received conditional marketing authorizations as well as emergency use authorizations in more than 45 countries around the world, including the United States and the European Union.

BioNTech’s employees have made a significant contribution to this initiative, working around the clock to harness the power of mRNA and apply it to this effort of fighting against the devastating pandemic. In addition, our partner companies and organizations have provided the company with research expertise, critical supply support, and valuable insights and assistance throughout the development and trial process. Without them, achieving this result only 11 months after the initiation of Project Lightspeed would not have been possible.

“To address a global challenge like COVID-19, we have undertaken a worldwide effort to develop a well-tolerated and effective vaccine as quickly as science and cutting-edge technology will allow,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Despite the damage caused by the virus, I have been inspired each day by the spirit of collaboration and scientific discovery. It is one of the greatest honors of my life to be involved in this effort and to play a role in helping the world regain a sense of normality. I would like to thank each and every person that helped make this a reality.”

BioNTech’s management and employees appreciate the relentlessly support of many companies. A full list of BioNTech’s partners supporting the COVID-19 project can be found below and at this link.

Our Partners:

A&C Biobuffer D-HCC Dopamine Healthcare Communication Maetrics QIAGEN
Acuitas Dätwyler Holding MACHEREY-NAGEL Ragon Institute of MGH, MIT and Harvard
Admedicum Delpharm Marble Pharma Consult Ramsay Pharma
Agilent Technologies Sales & Services Dermapharm Medidata RD-Biotech
Alexis Carpenter Consulting DHL medwiss-extern Real Life Sciences
ALFA Chemicals Discovery Life Sciences Merck Regeneron
Almac Clinical Services Dr. Liebscher Consulting Merck Chemicals Rentschler
Applied Critical Fluids Dunn Labortechnik Meso Scale Diagnostics Repligen Corporation
Aristo Group Entourage Pharma Consulting Miltenyi Biotec Sartorius Lab Instruments
auceris Eppendorf Vertrieb Deutschland mpütranslations Sartorius Stedim Biotech
Avanti Polar Lipids Eurobio Scientific Mundicare Schott
Avia Pharma Eurofins Genomics Germany nerbe plus Siegfried
Baxter Evonik Industries New England Biolabs Siemens
Becton Dickinson Finsbury Glover Hering Corporation National Institutes of Health (NIH Sigma-Aldrich Chemie
Bexon Clinical Consulting Fisher Scientific Novartis Sino Biological Europe
Biaffin Fosun Pharma ONE LOGIC Sinus Event-Technik
BioCat Fraunhofer-Institut für Techno- und Wirtschaftsmathematik ITWM ORIGIO Clinical Monitoring SOMI Solutions
BioLegend Europe FreshFields Bruckhaus Deringer Osborne Clarkeg Staburo
Biomay Gowling WLG Panhans Pharma Consul Stephenson Harwood
Biotrend Chemikalien Granzer Regulatory Consulting & Service Paul Hastings Stevenato Group
Biozol Diagnostica Vertrieb Greiner Bio-One Peak Scientific SyroCon Consulting
Brand Institute GlaxoSmithKline (GSK) Pfizer TCW
Carl Roth Heidrick & Struggles Phaidon International Tecan Deutschland
Catalent Hölzel Diagnostika Handels PharmaCentaur Tenthpin Management
CG Pharma Horváth & Partner PHARM-SOFT Dr. B. Rodu Thermo Fisher Scientific
 Chemgineering ICON PHMR THERON Management Advisors
 Choate Hall & Stewart Informa Pharma Intelligence Phoenix-Apotheke Mainz Topmedicare
CMS Legal Services  Instadeep Pixilicious Enterprises TriLink BioTechnologies
Cognigy K-Recruiting Plan@ IT Services TriRadial Solutions
Cole-Parmer Kerafast Polymun TRON
Consulimus Kissel Pharma Consulting portvier Trophic Communications
Consultants Korn Ferry Powell Gilbert Universitätsklinikum Frankfurt
Corning Knauer Precision Bioservices UniversitätsKlinikum Heidelberg
Covington LGC Genomics Precision for Medicin VisMederi
CRB Group Life Technologies (Thermo Fisher Scientific) Profishop-Bremee VWR International
Croda International LKF-Laboratorium für Klinische Forschung ProfiLab24 Waters
CRS Clinical Research Services Mannheim   Progedo WE Communications
    Progressive Recruitment World Courrier
    pure 11 ZSP Patentanwälte
    PriceWaterhouseCoopers (PwC)  

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit

BioNTech Contacts:

Media Relations
Jasmina Alatovic
+49 6131 9084-0

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074